DMSO Cryopreserved Platelets in Cardiopulmonary Bypass Surgery (CRYPTICS)

Cellphire Therapeutics, Inc.161 enrolled

Overview

A randomized, parallel group, active comparator-controlled trial to evaluate the non-inferiority or superiority of Cryopreserved Platelets with Liquid Stored Platelets in controlling blood loss in patients undergoing Cardiopulmonary Bypass Surgery. Patients planning to undergo Cardiopulmonary Bypass Surgery with risk factors for significant bleeding post-surgery will be approached. Subjects will be randomized in a 1:1 ratio to receive either Cryopreserved Platelets or Liquid Stored Platelets. Eligible subjects will undergo Cardiopulmonary Bypass Surgery and at the completion of bypass and heparin reversal subjects will likely be assessed for eligibility before coming off bypass. Study platelets will be given either intraoperatively after heparin reversal and return of active clotting time (ACT) to \< 140 sec or post operatively (after chest closure). A single unblinded interim analysis on the primary efficacy endpoint will be performed for this study after 75% of the planned number of mITT subjects are treated (i.e., after 150 mITT subjects are treated, irrespective of the number of subjects in each treatment group).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

161

Conditions

Cardiac Surgery

Interventions

Human plateletsBIOLOGICAL

Platelets given to control bleeding

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Male or female, at least 18 years of age 2. Undergoing CPB surgery with at least one risk factor for post-surgical bleeding including: 1. All re-operative cardiac procedures. 2. Expected bypass \> 120 minutes. 3. Any combined cardiac surgery procedures (e.g. multiple valve, valve/CABG). 4. Any procedure that in the estimation of the surgical attending, has a high likelihood of receiving platelets 3. Ability to comprehend and willingness to sign informed consent. 4. If female of childbearing potential, have a negative pregnancy test on the day of the surgery and prior to the surgery agrees to use a method of highly effective birth control from the time of consent through the end of the safety follow-up period (Day 6 or discharge from hospital, whichever is earlier). Note: women must have been surgically sterilized \[bilateral tubal ligation, bilateral oophorectomy, total hysterectomy) or postmenopausal (≥50 years of age and continuous amenorrhea for 24 months) to be considered non-childbearing potential. Exclusion Criteria: Subjects meeting any of the following criteria will be excluded from the study: 1. Undergoing any of the following surgical procedures: 1. Coronary artery bypass surgery alone 2. Implantation of ventricular assist device 3. Thoracoabdominal aortic aneurysm repair 2. Known or suspected pregnancy or breastfeeding 3. History of any major unprovoked thrombotic events 4. History of heparin-inducted thrombocytopenia 5. Active infection treated with antibiotics 6. Refuse transfusion of blood products for religious or other reasons 7. Previous enrollment in this study 8. Immune thrombocytopenic purpura 9. Known allergy to DMSO 10. In the judgement of the investigator, is not a good candidate for the study

Locations (16)

University of Alabama

Birmingham, Alabama, United States

University of Colorado

Aurora, Colorado, United States

Outcomes

Primary Outcomes

Primary Efficacy Endpoint assessed from time zero until the drain tubes are removed or 24 hours post time zero.

Total volume of chest tube drainage assessed by measurement of the volume of blood collected from the mediastinal and pleural drains from "time zero", the time of 1) chest closure or equivalent, 2) chest tubes or equivalent are attached to a graduated post drainage system, and 3) with suction (defined as time zero for analytical purposes) determined in mL/kg every hour during the first 12 hours and at 6-hour intervals thereafter, for up to 24 hours or chest tube removal (whichever is earlier).

Time frame: From "time zero" until the drain tubes are removed or 24 hours post time zero, whichever is earlier

Secondary Outcomes

Secondary Efficacy Endpoint assessed from time zero until the drain tubes are removed or 24 hours post time zero.

The primary endpoint given in mL/kg

Time frame: From "time zero" until the drain tubes are removed or 24 hours post time zero, whichever is earlier

Secondary Efficacy Endpoint assessed at 6 hours interval through 24 hours post time zero or when the chest tubes are removed.

Chest tube drainage volume (mL) collected at 6 hours intervals through 24 hours post time zero or tube removal, whichever is earlier.

Time frame: 6 hours intervals through 24 hours post time zero or when chest tubes are removed, whichever is earlier.

Secondary Efficacy Endpoint at 6 hours intervals through 24 hours post time zero or when chest tubes are removed

Drainage rate (mL/hr) collected at 6 hours intervals through 24 hours post time zero or when chest tube are removed, whichever is earlier.

Time frame: 6 hours intervals through 24 hours post time zero or when chest tubes are removed, whichever is earlier

Secondary Efficacy Endpoint assessed at the end of first study platelet transfusion through 24-hour post heparin reversal (Efficacy follow-up period)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.